Cargando…

Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling

This study investigated the antitumor effects of foretinib on triple-negative breast cancer cells MDA-MB-231 xenograft tumors in vivo underlying phosphorylated mesenchymal to epithelial transition (p-MET)/ hepatocyte growth factor (HGF)-related mechanism, as well as its pharmacokinetic characteristi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Xiwei, Meng, Xiangrui, He, Qingfeng, Xiang, Xiaoqiang, Shi, Yufei, Zhu, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821162/
https://www.ncbi.nlm.nih.gov/pubmed/36614199
http://dx.doi.org/10.3390/ijms24010757
_version_ 1784865631848366080
author Ji, Xiwei
Meng, Xiangrui
He, Qingfeng
Xiang, Xiaoqiang
Shi, Yufei
Zhu, Xiao
author_facet Ji, Xiwei
Meng, Xiangrui
He, Qingfeng
Xiang, Xiaoqiang
Shi, Yufei
Zhu, Xiao
author_sort Ji, Xiwei
collection PubMed
description This study investigated the antitumor effects of foretinib on triple-negative breast cancer cells MDA-MB-231 xenograft tumors in vivo underlying phosphorylated mesenchymal to epithelial transition (p-MET)/ hepatocyte growth factor (HGF)-related mechanism, as well as its pharmacokinetic characteristics. The MDA-MB-231 human breast cancer cell line was used for in vitro experiments, and the tumor xenograft model was established for in vivo experiments. MDA-MB-231 xenograft mice received oral foretinib (15 or 50 mg/kg/day) or vehicle for 18 days. The xenograft tumors were collected. Protein expressions of p-MET and HGF were examined with Western blotting and immunohistochemical staining. The mRNA expression of MET was examined with real-time PCR. Blood samples were collected from the mice treated with foretinib under different doses of 2, 10, and 50 mg/kg, and the pharmacokinetic profiles of foretinib were evaluated. We found that foretinib treatment caused a significant inhibition in tumor growth in a dose-dependent manner, whereas the continuous administration did not result in weight loss in treated nude mice. In both MDA-MB-231 cells and xenograft tumors, foretinib suppressed the expression of p-MET and HGF. These findings reveal that the decrease of p-MET and HGF may play an important role in the anti-breast cancer properties of foretinib.
format Online
Article
Text
id pubmed-9821162
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98211622023-01-07 Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling Ji, Xiwei Meng, Xiangrui He, Qingfeng Xiang, Xiaoqiang Shi, Yufei Zhu, Xiao Int J Mol Sci Article This study investigated the antitumor effects of foretinib on triple-negative breast cancer cells MDA-MB-231 xenograft tumors in vivo underlying phosphorylated mesenchymal to epithelial transition (p-MET)/ hepatocyte growth factor (HGF)-related mechanism, as well as its pharmacokinetic characteristics. The MDA-MB-231 human breast cancer cell line was used for in vitro experiments, and the tumor xenograft model was established for in vivo experiments. MDA-MB-231 xenograft mice received oral foretinib (15 or 50 mg/kg/day) or vehicle for 18 days. The xenograft tumors were collected. Protein expressions of p-MET and HGF were examined with Western blotting and immunohistochemical staining. The mRNA expression of MET was examined with real-time PCR. Blood samples were collected from the mice treated with foretinib under different doses of 2, 10, and 50 mg/kg, and the pharmacokinetic profiles of foretinib were evaluated. We found that foretinib treatment caused a significant inhibition in tumor growth in a dose-dependent manner, whereas the continuous administration did not result in weight loss in treated nude mice. In both MDA-MB-231 cells and xenograft tumors, foretinib suppressed the expression of p-MET and HGF. These findings reveal that the decrease of p-MET and HGF may play an important role in the anti-breast cancer properties of foretinib. MDPI 2023-01-01 /pmc/articles/PMC9821162/ /pubmed/36614199 http://dx.doi.org/10.3390/ijms24010757 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ji, Xiwei
Meng, Xiangrui
He, Qingfeng
Xiang, Xiaoqiang
Shi, Yufei
Zhu, Xiao
Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling
title Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling
title_full Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling
title_fullStr Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling
title_full_unstemmed Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling
title_short Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling
title_sort foretinib is effective against triple-negative breast cancer cells mda-mb-231 in vitro and in vivo by down-regulating p-met/hgf signaling
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821162/
https://www.ncbi.nlm.nih.gov/pubmed/36614199
http://dx.doi.org/10.3390/ijms24010757
work_keys_str_mv AT jixiwei foretinibiseffectiveagainsttriplenegativebreastcancercellsmdamb231invitroandinvivobydownregulatingpmethgfsignaling
AT mengxiangrui foretinibiseffectiveagainsttriplenegativebreastcancercellsmdamb231invitroandinvivobydownregulatingpmethgfsignaling
AT heqingfeng foretinibiseffectiveagainsttriplenegativebreastcancercellsmdamb231invitroandinvivobydownregulatingpmethgfsignaling
AT xiangxiaoqiang foretinibiseffectiveagainsttriplenegativebreastcancercellsmdamb231invitroandinvivobydownregulatingpmethgfsignaling
AT shiyufei foretinibiseffectiveagainsttriplenegativebreastcancercellsmdamb231invitroandinvivobydownregulatingpmethgfsignaling
AT zhuxiao foretinibiseffectiveagainsttriplenegativebreastcancercellsmdamb231invitroandinvivobydownregulatingpmethgfsignaling